All Stories

  1. A world view: Considerations of sociocultural diversity in the study of subjective cognitive decline in Alzheimer's disease and related dementias
  2. Message From the Editors to Our Reviewers
  3. Association between renin angiotensin system and cognitive outcomes over 15 years: The Look AHEAD study
  4. Acknowledgement to Reviewers
  5. Validated measures of agitation in neurocognitive disorders: A systematic review of 41 scales and their alignment with International Psychogeriatric Association criteria
  6. Fluid Biomarkers of Motor and Non-Motor Experiences of Daily Living in Dementia with Lewy Bodies and Alzheimer’s Disease
  7. Acknowledgement to Reviewers
  8. International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the SIGNATURE initiative
  9. Omics-AD—A multimodal biomarker study on cognitive decline and neuropsychiatric symptoms: Design and cohort characteristics
  10. The measurement of agitation in neurocognitive disorders: A systematic review
  11. Plasma biomarkers in neuropsychiatric syndromes: A narrative review
  12. Disentangling the Clinical and Neuroimaging Spectrum of Neuronal α-Synucleinopathies
  13. Acknowledgement to Reviewers
  14. List of reviewers
  15. Atrophy patterns of deep gray matter nuclei in Alzheimer's disease and frontotemporal dementia
  16. The relationships between cerebrospinal fluid neurofilament light chain and hippocampal atrophy with cognitive decline
  17. Leveraging multiomic approaches to elucidate mechanisms of heterogeneity in Alzheimer's disease: Neuropsychiatric symptoms, co‐pathologies, and sex differences
  18. Message From the Editors to Our Reviewers
  19. International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the SIGNATURE initiative
  20. APOE -mediated associations of promoter variants of GRIN1 and GRIN2B with behavioral symptoms and age at onset of Alzheimer’s disease dementia
  21. Understanding barriers and optimizing socio‐cognitive assessment in the diagnosis of neurocognitive disorders
  22. Analysis and interpretation of inflammatory fluid markers in Alzheimer’s disease: a roadmap for standardization
  23. Message From the Editors to Our Reviewers
  24. The problem of multiple adjustments in the assessment of minimal clinically important differences
  25. Biomarkers in Clinical Trials of Alzheimer Disease: An Overview
  26. Associations between selected genetic variants and lipid profile variability in response to statins in Alzheimer’s disease: a prospective observational study
  27. List of Reviewers
  28. Anthropometric and Demographic Features Affect the Interpretation of Cerebrospinal Fluid Biomarkers in Patients with Different Dementia Syndromes and Cognitively Healthy Adults
  29. Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease
  30. Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease
  31. Assessing Independence in Activities of Daily Living and Quality of Life in Patients with Dementia with Lewy Bodies
  32. Message From the Editors to Our Reviewers
  33. Shedding Light on the Effects of Blood Pressure on Cognitive Decline and Dementia Risk by Way of Neurobiological Evidence
  34. Biofluid Activity and Levels of the Angiotensin-converting Enzyme Are Surrogates for Diverse Cerebrospinal Fluid Amyloid-beta Effects in Dementia with Lewy Bodies and Alzheimer’s Dementia (P6-9.001)
  35. Message From the Editors to Our Reviewers
  36. Acknowledgement to Reviewers
  37. List of Reviewers
  38. GRIN2B genotypes and APOE haplotypes affect the age at onset of Alzheimer’s dementia as well as variations in dementia staging according to the use of Memantine
  39. Differential performance of cerebrospinal fluid biomarker ratios and formulas to discriminate dementia with Lewy bodies from Alzheimer’s dementia and cognitively healthy people reflects high level of amyloidosis across dementia syndromes
  40. Biofluid activity and levels of the angiotensin‐converting enzyme may translate into distinct neuropsychiatric symptoms associated with cerebrospinal fluid amyloid‐beta effects and tauopathy in dementia with Lewy bodies and Alzheimer’s dementia
  41. Disparities in neuropsychiatric symptom clusters across dementia diagnoses within Lewy body dementia syndromes and Alzheimer’s dementia
  42. Variations in metabolic risk factors for dementia do not affect APOE‐mediated cognitive or functional decline in patients with Alzheimer’s disease from São Paulo, Brazil
  43. Pitfalls and biases in neuroepidemiological studies of COVID-19 and the nervous system: a critical appraisal of the current evidence and future directions
  44. Pharmacogenetics of angiotensin modulators according to APOE-ε4 alleles and the ACE insertion/deletion polymorphism in Alzheimer’s disease
  45. Message From the Editors to Our Reviewers
  46. Looking Behind the Curtain: Patient Stratification According to Genetic or Demographic Factors May Yield Unexpected Results in Studies of Neurodegenerative Diseases
  47. Effects of the DICE Method to Improve Timely Recognition and Treatment of Neuropsychiatric Symptoms in Early Alzheimer’s Disease at the Memory Clinic: The BEAT-IT Study
  48. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer’s disease
  49. Lifestyle and pharmacological interventions in South America: Potential barriers for recruitment, implementation, and effectiveness
  50. Acknowledgement to Reviewers
  51. Message From the Editors to Our Reviewers
  52. List of Reviewers
  53. The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All
  54. Acknowledgement to Referees
  55. Acknowledgement
  56. APOE ε4 Carrier Status as Mediator of Effects of Psychotropic Drugs on Clinical Changes in Patients With Alzheimer’s Disease
  57. Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions
  58. Message From the Editors to Our Reviewers
  59. Pharmacogenetic Analyses of Therapeutic Effects of Lipophilic Statins on Cognitive and Functional Changes in Alzheimer’s Disease
  60. New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia
  61. The Viability of Treatment Conditioned to the Pathophysiology of Alzheimer’s Disease
  62. Vascular cognitive impairment and dementia: An early career researcher perspective
  63. Message From the Editors to Our Reviewers
  64. List of Reviewers
  65. Acknowledgement
  66. Reviewer Acknowledgement, 2021
  67. Message From the Editors to Our Reviewers
  68. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer’s Disease and Cognitively Healthy People
  69. Abstract Anne H Berman – incoming ISBM president
  70. Behavioural effects of the ACE insertion/deletion polymorphism in Alzheimer’s disease depend upon stratification according to APOE-ϵ4 carrier status
  71. Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe
  72. APOE-ɛ4-mediated correlates of cerebrospinal fluid biomarkers of amyloidosis and neurodegeneration with cognition and functionality in dementia with Lewy bodies compared with Alzheimer’s dementia and cognitively healthy people (49)
  73. Acknowledgements to Reviewers
  74. Swallowing in behavioral variant frontotemporal dementia
  75. Message From the Editors to Our Reviewers
  76. List of Reviewers
  77. Klüver‐Bucy syndrome due to stroke in the left temporal lobe
  78. Vascular cognitive impairment due to dilated perivascular spaces in putamen: Connections with the ventrolateral prefrontal cortex and neurological deficits
  79. Dementia in Latin America: Paving the way toward a regional action plan
  80. Correlates of neuropsychiatric and motor tests with language assessment in patients with Lewy body dementia
  81. Selected LDLR and APOE Polymorphisms Affect Cognitive and Functional Response to Lipophilic Statins in Alzheimer’s Disease
  82. Neuropsychiatric feature profiles of patients with Lewy body dementia
  83. Agitation and impulsivity in mid and late life as possible risk markers for incident dementia
  84. The impact of SARS‐CoV‐2 in dementia across Latin America: A call for an urgent regional plan and coordinated response
  85. Acknowledgments
  86. CEREBROSPINAL-FLUID-BASED BIOMARKER EVIDENCE OF AMYLOIDOGENESIS IN DEMENTIA WITH LEWY BODIES DEPENDS UPON APOE-ε4 CARRIER STATUS
  87. PRISON WITHOUT WALLS: A CASE REPORT OF SEMANTIC VARIANT PRIMARY PROGRESSIVE APHASIA
  88. GRIN2A GENOTYPES AND APOE HAPLOTYPES AFFECT THE AGE AT ONSET OF ALZHEIMER’S DEMENTIA BUT NOT FUNCTIONAL OR COGNITIVE RESPONSE TO MEMANTINE
  89. FOOT CLEARANCE WHILE STEPPING-IN-PLACE AS A TOOL TO SALIENT COGNITIVE AND MOTOR OUTPUT DEFICITS IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A PRELIMINARY STUDY
  90. BEHAVIORAL CORRELATES OF CEREBROSPINAL FLUID BIOMARKERS ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER’S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE
  91. Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
  92. Acknowledgements to Reviewers
  93. Acknowledgments
  94. Influence of Socioeconomic Status and Stress Over Quality of Sleep: A Systematic Review
  95. Author Index
  96. Keyword Index
  97. Movement Disorders: Volume 33, Number S2, October 2018
  98. Abstracts
  99. Lifetime Risk Factors for Functional and Cognitive Outcomes in Patients with Alzheimer’s Disease
  100. GENETICALLY MEDIATED LIFETIME RISK FACTORS FOR COGNITIVE AND FUNCTIONAL DECLINE IN PATIENTS WITH ALZHEIMER’S DEMENTIA FROM SÃO PAULO, BRAZIL
  101. APOE-DEPENDENT PSYCHOTROPIC EFFECTS OVER CLINICAL CHANGES IN ALZHEIMER’S DISEASE DEMENTIA
  102. COGNITIVE AND FUNCTIONAL CORRELATES OF CEREBROSPINAL FLUID CONCENTRATIONS OF AMINOACIDS AND MONOAMINE METABOLITES ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER’S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE
  103. COGNITIVE CHANGES ARE PHARMACOGENETICALLY MEDIATED BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN PATIENTS WITH ALZHEIMER’S DISEASE DEMENTIA
  104. Behavioral correlates of cerebrospinal fluid concentrations of aminoacids and monoamine metabolites according to APOE-ɛ4 carrier status in dementia with Lewy bodies compared with Alzheimer’s dementia and cognitively healthy people (P4.190)
  105. Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia
  106. Acknowledgement to reviewers
  107. Effects of APOE haplotypes and measures of cardiovascular risk over gender-dependent cognitive and functional changes in one year in Alzheimer's disease
  108. Acknowledgements to Reviewers
  109. ePresentation
  110. ePoster Session
  111. Author Index
  112. Issue Information
  113. Associations of cerebrovascular metabolism genotypes with neuropsychiatric symptoms and age at onset of Alzheimer’s disease dementia
  114. Longitudinal lipid profile variations and clinical change in Alzheimer's disease dementia
  115. Reviewers for International Journal of Stroke 2016
  116. Neurological impressions on the organization of language networks in the human brain
  117. GRIN1 GENOTYPES AND APOE GENE HAPLOTYPES AFFECT THE AGE AT ONSET OF ALZHEIMER'S DISEASE DEMENTIA BUT NOT COGNITIVE OR FUNCTIONAL RESPONSE TO MEMANTINE
  118. EFFECTS OF APOE GENE HAPLOTYPES AND MEASURES OF CARDIOVASCULAR RISK OVER COGNITIVE AND FUNCTIONAL DECLINE IN ONE YEAR IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA
  119. MOTOR ASPECTS OF DAILY LIVING FOLLOW COGNITIVE AND FUNCTIONAL STATUS BUT NOT BEHAVIOURAL SYMPTOMS IN PATIENTS WITH LEWY BODY DEMENTIA SYNDROMES
  120. Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
  121. Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease
  122. Swallowing in primary progressive aphasia
  123. Predictors of Cognitive and Functional Decline in Patients With Alzheimer Disease Dementia From Brazil
  124. Associations of Blood Pressure with Functional and Cognitive Changes in Patients with Alzheimer's Disease
  125. The Controversial Influence of Cerebrovascular Risk Factors over Pathological Mechanisms of Late-Onset Alzheimer's Disease Dementia
  126. Risk factors for cognitive and functional change in one year in patients with Alzheimer's disease dementia from São Paulo, Brazil
  127. Correlations among cognitive and behavioural assessments in patients with dementia due to Alzheimer's disease
  128. Contrasts Between Patients With Lewy Body Dementia Syndromes and APOE-ε3/ε3 Patients With Late-onset Alzheimer Disease Dementia
  129. A patient with agrammatic primary progressive aphasia developing frontotemporal dementia
  130. Pharmacogenetics of cerebrovascular metabolism modulators in dementia due to Alzheimer’s disease
  131. Assessment of sleep satisfaction in patients with dementia due to Alzheimer’s disease
  132. Acknowledgements
  133. Is there correlation between cognition and functionality in severe dementia? The value of a performance-based ecological assessment for Alzheimer’s disease
  134. Brain-Penetrating Angiotensin-Converting Enzyme Inhibitors and Cognitive Change in Patients with Dementia due to Alzheimer's Disease
  135. P2‐024: PHARMACOGENETICS OF BRAIN‐PENETRATING ANGIOTENSIN‐CONVERTING ENZYME INHIBITORS IN DEMENTIA DUE TO ALZHEIMER'S DISEASE
  136. P2‐025: PHARMACOGENETICS OF CHOLESTEROL‐LOWERING DRUGS IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE
  137. P3‐333: RISK FACTORS FOR COGNITIVE CHANGE IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE FROM SÃO PAULO, BRAZIL
  138. Caregiver awareness of cerebrovascular risk of patients with dementia due to Alzheimer's disease in São Paulo, Brazil
  139. Abstracts from the 29th CINP World Congress of Neuropsychopharmacology, Vancouver, Canada, 22–26 June 2014
  140. Risk Factors for Cognitive Change in Patients with Dementia Due to Alzheimer’s Disease (P5.210)
  141. Pharmacogenetics of Lipid Metabolism Modulators in Patients with Dementia Due to Alzheimer’s Disease (P5.223)
  142. Risk factors for age at onset of dementia due to Alzheimer's disease in a sample of patients with low mean schooling from São Paulo, Brazil
  143. 2013 Reviewer Acknowledgement
  144. Assessment of risk factors for earlier onset of sporadic Alzheimer′s disease dementia
  145. Educational bias in the assessment of severe dementia: Brazilian cutoffs for severe Mini-Mental State Examination
  146. Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease
  147. Cognitive Impairment in Fibromyalgia
  148. Impact of Cardiovascular Risk over the Rate of Progression of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from São Paulo, Brazil (IN6-1.009)
  149. Impact of Cardiovascular Risk over the Rate of Progression of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from São Paulo, Brazil (P07.136)
  150. Communicating with the non-dominant hemisphere: Implications for neurological rehabilitation
  151. Normal pressure hydrocephalus in the spectrum of neurological complications of systemic lupus erythematosus
  152. A patient with primary progressive aphasia developing dementia due to Alzheimer's disease
  153. Impact of Cerebrovascular Risk Factors over Age of Onset of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from Sao Paulo, Brazil (P04.201)
  154. 2012 Annual Meeting Sunday, October 7, 2012 Poster Session Abstracts
  155. A topographic study on the evaluation of speech and language in the acute phase of a first stroke
  156. P1‐453: Functional independence and tests of cognitive assessment in patients with Alzheimer's disease
  157. P2‐153: Impact of cardiovascular risk factors over age of Alzheimer's disease onset in patients with low schooling
  158. P3‐260: Impact of schooling and cardiovascular risk factors over the rate of progression of Alzheimer's disease
  159. Twenty-first Meeting of the European Neurological Society 28–31 May, 2011
  160. Global aphasia as a predictor of mortality in the acute phase of a first stroke
  161. Semantic aphasia as a sole manifestation of acute stroke
  162. Preliminary topographic diagnosis of ischemic brain injuries according to speech and language disorders
  163. Short-term prognosis for speech and language in first stroke patients
  164. Hypoglossal nerve palsy as the sole manifestation of spontaneous internal carotid artery dissection
  165. Author Index
  166. Abstracts
  167. 0661 Primitive Neuroectodermal Tumor of the brain presenting with late spinal cord dissemination after surgical treatment and complementary radiotherapy and chemotherapy
  168. 1499 Trends on the use of complementary exams in modern day neurology: how to teach the patient about the tools actually needed for the investigation without conflicting knowledge with popular wisdom